Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should Advent's revenue give you that answe ?
Goal post change every month. Next thing you know we're at 720 days. People think it's fud but soon they'll eat what they claimed to be fud.
800 X 250k= 200 million $!
Where has that money gone??
Cancer vaccines: platforms and current progress
10 January 2025
"DCVax-L represents another autologous tumor lysate-loaded DC vaccine, notable for its capacity to target a comprehensive antigenic library through tumor lysates, thus optimizing antigen presentation [68, 122, 123]. It showed promising efficacy in a phase III trial involving patients with newly diagnosed gliomas (nGBM) and recurrent gliomas (rGBM). Specifically, the median OS was 19.3 months for the DCVax-L group compared to 16.5 months for the placebo group among nGBM patients, with 5-year survival rates of 13.0% versus 5.7%, respectively. Additionally, patients treated with DCVax-L experienced a 20% relative reduction in mortality risk over time compared to those receiving standard therapy. For rGBM patients, the median OS was 13.2 months for the DCVax-L group, compared to 7.8 months for the placebo group" [124].
#dcvax $nwbo #GBMeme
— Peter Davis (@peter_brit) April 3, 2025
Cancer vaccines: platforms and current progress
10 January 2025
"DCVax-L represents another autologous tumor lysate-loaded DC vaccine, notable for its capacity to target a comprehensive antigenic library through tumor lysates, thus optimizing antigen… pic.twitter.com/U0vB8xRvp6
Where are you looking at for this data? I see marketing authorisations granted up to March 14th and it's more like 40 per month.
Yeah, we’re still at bat.
Are we approved yet?? I heard from many on here that we would be approved 180 days after submission November 2023. It is way past that. When's approval??
The last time MHRA approved a drug was Feb 28, 25, more then a month ago. They usually approve at least two to three drugs a month based their recent posted record. The next drug up for approval got to be DCVAX-L. JMHO. I am tire of waiting just like you all, but got be very very soon.
Wondering if Tunnelvision had any thoughts about the 10k in relation to his ongoing due diligence project.
I hope your concern is misplaced but if it does happen there is one thing for sure:
Many of the same folks emoji-bombing your post and thereby tacitly denying the risk of a reverse split will shamelessly flip to pretending that a reverse split is neutral or actually good for shareholders and will defend it as a brilliant good by management and not as what would be the capstone of years of letting us down.
Hopefully I never have to be proven right and we never see an R/S. Being right has not been profitable.
If you read the article, it says the entity that did the study called them Shady. The Alliance for Consumers (AFC)
From the article: Which it dubs the "Shady Eight." Meaning the Alliance for Consumers.
I'm not calling them Shady. I was just asking if Cohen Milstein was our lawyer firm.
I don't know why your post got taken down. I didn't report it. I could care less what people post on this crooked site.
Yes That's lack of guidance And that was DI bull....ing to wait for So typical
Why did you expect any guidance other than what was in the 10K. The company has said repeatedly that it will not comment on the application until there is a decision. That was said in the 10K.
So drawing any conclusion from the lack of guidance is a mistake.
Perhaps it would be fitting of this entire story to get approval on a day that looks to be setting up historically red?
georgeb - Here's something you may find thought provoking, and descriptive as to where NWBO stands today - I saw a brief clip of an interview with Tebetan Monk. The Monk explained that people misunderstood the actual meaning of Karma - "People think Karma is something that happens in the future, as a result of actions taken in the present." He clearly rejected that idea. "Karma describes people’s fear based tendency of waiting to live the life they want, preconditioned on something that needs to happen first." In other words, you wake up every day complaining about your situation or circumstances, while believing or expecting your circumstances will change. He said, "NO, where you are in the present is exactly where you deserve to be!" “That's Karma“ “To have the life you want to live, you must take action in the present to find it."
If I take Karma as an abstract construct to describe where NWBO is where it is today, I see everything that has taken place, good, bad, and or ugly, as experiences that were necessary to shape what NWBO has to offer today. So I reject notion that suggests, some other alternative actions may have been in the past taken, that would have produced a better potential outcome at present
…Or maybe you just consider me “Not invested” because management lost the last decade’s retail shareholders all their investment?
How do you know I’m not invested? This is a narrative the disciples have been pushing here since the beginning even as I constantly fight for legacy shareholders.
Perhaps the lawsuit’s real goal is to simply take down a prominent wealthy Republican? 🤔
Ones that work on contingency in medical field are called ambulance chasers .
Our Law Firm defending us, the little guy, is being called Shady in this article. What does everyone think of that? And before a mod takes down this comment like you did my last, please tell me why? The article is not taken down, but a comment asking why our law firm are being called "shady" by said article is somehow offensive.
Actually good thing is it can only go down 20 cents
46,000 Shareholders of record now, btw.
LOL! Did you even read the report? I'm sure it's not a one Party issue. I'm sure it goes on for both sides. It would be nice if Americans could agree that Any/All Waste, Fraud, & Abuse in our Government is intolerable. No matter where it is.
Cohen Milstein...Isn't that our lawyer firm?
"The report, released by Alliance for Consumers (AFC), highlights the deep Democratic ties of eight major consumer protection law firms — Morgan & Morgan, Lieff Cabraser, Motley Rice, Baron & Budd, Grant & Eisenhofer, Berger Montague, Cohen Milstein and Simmons Hanly — which it dubs the "Shady Eight."
https://www.foxnews.com/politics/exclusive-shady-trial-lawyer-pipeline-funneling-millions-democrats-report
Georgeb - They do say, "timing is everything."
Based on the after-hours news today (tariffs), tomorrow looks like it will be another dark red day, and I just hope our stock isn't too affected by it.
I remember LP using words like "home run" and when asked, if she would sell, "if they gave us an offer we couldn't refuse, anything is possible." IMHO, it was after the 2018 ASM, and before she bought Flaskworks, that she realized that she needed to develop the company much more broadly to approach anywhere near what her expectations were at the time. So she set in motion a game plan, which began with Flaskworks. There's no denying, it was brilliant and bold. In a small niche like immunotherapy, it must of reverberated enough to add clout to what was already on solid ground with UCLA. During the June 29th ASM, she listed what the company had achieved over the past 18 months, and pivoted, to what the company's objects would be over the next 18 months. It's been 9 months since then, and the recent 10K showed us a deep list of very substantial actions which has brought NWBO much closer on paper to be that "home run" or deserving of "an offer, we just can't refuse."
The exact percentage required for R/S approval can vary based on the company's bylaws and jurisdiction.
What % of the vote did they need for Bonuses?
An RS is not as difficult for them to execute as you are making it out to be.
Doc Logic,
Let's review the points your post made about nwbo. Note the spacing for readability.
- been around 29 years
- never produced a commercially available product
- never been profitable
- spent over a billion dollars along the way
- doesn’t go to investor conferences or hold quarterly calls
- still has 50,000+- shareholders backing them? If true, $6,000 per shareholder, less when you back out the insider holdings.
Just because the nwbo story is different does not make it positive.
ILT you love coincidences......Coincidence with Cannacord entering the deal and our MTD being denied?
I guarantee you that there is not going to be an ASM or special shareholders meeting between now and the MHRA decision where a vote will be put forward with the proposal to reverse split NWBO stock OR increase the A/S which they need 51% quorum on. If that is what you mean with a completely different share structure, that's not going to happen.
The company doesn’t have the financial structure to last another 3 months at their current burn rate.
If we go 3 more months without news, the company is going to have a completely different share structure whenever the decision is finally made.
On the other hand, it would seem LP isn't just smitten with the idea of avenging the death of her father due to cancer by finding a cure, but also, it suggests that she has a healthy appetite for making a lot of money. That keeps our mutual interest to maximize a fat return aligned.
100%
I'd wager some already know this is going to happen
The problem is the gap between now and whatever point in time approval happens. The company doesn’t have the financial structure to last another 3 months at their current burn rate. If we go 3 more months without news, the company is going to have a completely different share structure whenever the decision is finally made.
Retail is on a clock. I don’t like the thought of that when dealing with the slowest company in history.
The whales on the sideline are completely fine with waiting until the share structure is blown up and re-established. Anyone on the sideline right now is in great shape. The only people at risk is retail.
dbing - While there's never a shortage of one liners, I haven't heard details of LP's high value spending preferences before. I must say, buying two $6.5 million dollar homes, while currently living in a high value home at a time, when retail has sacrificed and endured for years is off-putting, to say the least. Personally, I couldn't do that with a clear conscience.
I thought it would be instructive to compare these two recent statements.
February 4, 2025 MHRA email
As you have already seen, the company has announced that they have submitted their application to us. We are working actively on this application, recognising the impact this medicine could potentially have.
Finally, please be assured we a progressing this application as rapidly as possible and in collaboration with the company.”
The Company is actively engaged in the ongoing process, and the Company has decided not to attend ASCO this year in order to stay focused on interactions with the MHRA and efforts to move forward as quickly as possible.
That doesn't sound like retail will be whipped out at all after MHRA approval as you claim?
On the other hand, they need money for operations and studies. So that would mean institutions/investors are the ones buying the diluted shares of stock.
or, there will be a new company after announcement, shorts are burned, and Linda would have controlling interest in new company.
or, SP is low because of dilution and lack of news. Lack of news due to mngmt not being up to date on social media and everyone is just waiting for approval.
I don't see LL being comfortable with SP artificially being kept low since it affects money used for her work.
Second, she is under the thumb of institutional investors. They aren't allowed to buy in unless certain conditions are met (minimum price, minimum market cap, etc). The institutions want to buy in as low as possible, but the only binary they can rely on to hit the minimum requirements is approval. Linda has to play ball to get their investments, and they have told her to keep the price as low as possible before approval by not releasing any positive news until after. They can't buy in right now because if they get caught with this on their books, especially if it gets rejected, they'll get a wrist slap or worse. But on approval, they know their buyin along with market response will hit the minimum requirements. If Linda was releasing PR's detailing what is in the 10K, the price would easily be over $1 and these guys would get 20% or less when buying compared to today's suppressed prices. I want to be clear, the company explicitly told me that institutions and large investors told them not to release news until after approval. That's not speculation, that's not what I gleaned from the conversation, that was told to me as a matter of fact. Whether you believe them is up to you.
Haven't been here in quite a while and this stock was too painful to follow.
Is there a new date when the UK will either vote yes or no or ask for more information?
Never did I think we would be getting close to its all-time low.
So many on here thought taking $5 a share was an insult. That price sailed many moons ago.
I would be happy with 60¢ but that might be too much to ask for. Almost a 300% gain from here would be amazing.
I remember when many on here wouldn't take $25 or even $50 share.
Some think a lawsuit will bring in significant money to the shareholder. I never held any hope of getting even 1¢ a share in a lawsuit.
It's so hard to win and if and when you do the only ones making $$$ are the lawyers.
IN MY OPINION, if LP can now get $5/sh she would take it in a New York minute. For me, I would take 60¢/sh tomorrow.
"FeMike said:
I want to be clear, the company explicitly told me that institutions and large investors told them not to release news until after approval. That's not speculation, that's not what I gleaned from the conversation, that was told to me as a matter of fact. Whether you believe them is up to you."
ok, that would make sense as to news being withheld to keep price low. An institution and/or investor would want as many shares as cheap as possible. It would also put the kibosh on those posts that claim they are being silent because any news would be used against them.
On the other hand, they need money for operations and studies. So that would mean institutions/investors are the ones buying the diluted shares of stock. Which makes no sense because there would have to be a written agreement guaranteeing funding continuing as long as dilution is continuing. And once approval is granted, then what? SP rises and institutions/large investors sell? Why not just sell warrants or get more loans for guaranteed income and guaranteed price? If there was a B/O, the buying company would want SP higher to justify B/O price to shareholders.
sounds like a conspiracy theory.
If Linda was releasing PR's detailing what is in the 10K, the price would easily be over $1 and these guys would get 20% or less when buying compared to today's suppressed prices. I want to be clear, the company explicitly told me that institutions and large investors told them not to release news until after approval. That's not speculation, that's not what I gleaned from the conversation, that was told to me as a matter of fact. Whether you believe them is up to you.
My response was to post. 758582bu FeMike
Excellent explanation Very informative and unfortunately very true
If true, that would explain why the complementary collaboration was absent in the 10k but DI stated all negotiations and potential collaborations were still on the table.
Hard to believe the amount of grifting going on here. No wonder she can't attract any big investors shes so fucking shady...but I wouldn't call her slim shady.
Followers
|
1718
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
758654
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators skitahoe Steady_T sentiment_stocks CaptainObvious Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |